Keyword: Samsung Bioepis

Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.

Korean CDMO Samsung BioLogics has won FDA approval for its first finished product at the second of three plants built in rapid succession.  

Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.

South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.

Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.

Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.

China conditionally approves Merck's Gardasil 9; Biogen looks to up its stake in Samsung Bioepis; WuXi plots a series of major expansions; and more.

Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.

Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.

J&J's Remicade fell victim to biosimilar competition in Europe and the U.S., but the copycats' impact has been quite different in the two regions.